Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency


How health care investors deal with Donald Trump as the next U.S. president and Republicans maintaining control of Congress is hard to forecast because few envisioned this scenario playing out. How health care investors deal with Donald Trump as the next U.S. president and Republicans maintaining control of Congress -- the outcome of Tuesday's election -- is hard to forecast because few envisioned this scenario playing out.



from Biotech News